Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
about
Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment OutcomesNotes for developing a molecular test for the full characterization of circulating tumor cellsCurrent Status of CTCs as Liquid Biopsy in Lung Cancer and Future DirectionsFragment Length of Circulating Tumor DNAEmerging technologies for salivaomics in cancer detectionClinical applications of liquid biopsies in gastrointestinal oncologyOrigins, structures, and functions of circulating DNA in oncologyFeasibility of multiplexed gene mutation detection in plasma samples of colorectal cancer patients by mass spectrometric genotyping.Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer TypesPost surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer.Mutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platformCirculating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types.Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCRComparison of genetic and epigenetic alterations of primary tumors and matched plasma samples in patients with colorectal cancerMeta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.SNPase-ARMS qPCR: Ultrasensitive Mutation-Based Detection of Cell-Free Tumor DNA in Melanoma Patients.Single-Tubed Wild-Type Blocking Quantitative PCR Detection Assay for the Sensitive Detection of Codon 12 and 13 KRAS Mutations.Cancer biomarker discovery and validation.Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD.A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomasPNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancerLow Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report.Prognostic value of circulating tumor DNA in patients with colon cancer: Systematic review.RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics.Effectiveness of circulating tumor DNA for detection of KRAS gene mutations in colorectal cancer patients: a meta-analysis.Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer.Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB)PIK3CA mutation detection in metastatic biliary cancer using cell-free DNACirculating Cell Free DNA in the Diagnosis of Trophoblastic TumorsKRAS G12V Mutation Detection by Droplet Digital PCR in Circulating Cell-Free DNA of Colorectal Cancer PatientsChanging paradigm of cancer therapy: precision medicine by next-generation sequencing.Establishment and application of a real-time loop-mediated isothermal amplification system for the detection of CYP2C19 polymorphisms.
P2860
Q26765922-84DF1C8E-6ECA-4760-ADC9-A7345D3FF273Q26778913-60701545-3F6E-4CE0-BBCA-ED547EF00AE0Q26781333-359C2606-25C5-43B6-ACB8-B7C811823125Q27308628-803EC2EB-E702-43F2-847A-F7858228F83AQ28069566-5FC84A86-6B99-4562-9EC1-45C1AF68DCC3Q28073730-362CDD83-87E3-408D-B54E-6F14511948ADQ30249103-E37CF8EC-3882-425F-9F4D-C711444370F0Q33620743-77488FFE-57A7-4718-99B9-B5D46892665AQ33673752-4B12EC4E-F847-445F-ADC9-5B6B37949698Q33679694-D9A2AB12-27E3-47D4-9171-0349BDBF6783Q34457501-6F26C68A-1ECE-4F8C-85C2-78543EBBF987Q34457638-4B26F8CD-A103-417C-8E0D-10E3C52B006AQ34662946-7BB27837-E310-4194-A96A-8B0DDB36CB01Q34748747-A3172C14-BA30-42DC-852D-C0E425A79EDEQ35068013-D7C7FAB1-6AD3-4357-BE43-49B66EBF8B24Q35576801-208CE9B5-168E-439B-96FC-AE7D9635CD91Q35709696-7A4811D3-52D4-4E10-A022-6B9D24989BDCQ35828697-A62B06A2-DB29-460C-8FB5-7F7D33F55327Q35839745-664EDC50-A75B-4AA7-ADB7-12124E6E6EFCQ35877954-2A1D483E-62EE-424F-9FA9-4B536BF1E3B2Q35879887-71866EF6-F2FB-4932-961D-C69416C64EA5Q36038684-AF475617-4860-40C0-AE04-227F5CBE8E10Q36091092-6A97257C-BE01-47BF-A472-117DAC91D40FQ36103228-E2F6E22B-BB05-4276-BC25-CBE80A1056AFQ36104839-308C31AA-B36B-4F7D-802E-362BE9DC446DQ36188885-C4AE6827-0F66-428C-B4A3-5387AB301C5CQ36233903-E6C3360B-6F46-40D5-A8A0-B6B494DEDA45Q36243135-62F794A9-3F94-464B-8B07-109FBC0F98B9Q36277022-B8C5B381-533D-4FAD-B576-D6B13257B86EQ36278318-BE3043EC-748F-4977-A219-8E6A61BF256AQ36292534-0B46FB67-275C-4FFC-B200-73114D8A7D49Q36318273-22D3F67F-E692-4439-A019-A4B86415C0F4Q36378903-516C4BCD-7623-410B-AA9E-C87B5D314390Q36416491-C1D6FE77-00E1-43D9-BFB0-AD9C85AE6F37Q36430821-5AD3E444-F280-467F-8C89-3CE183A974B7Q36545534-6949DF7A-DF64-4EEA-8E3A-2D7B6B04F682Q36645051-EAB258EB-5D63-47B4-8D26-CBC2AE09B0CBQ36846985-0CF1AA38-A3C6-4F21-AF6B-EA7714E45F9DQ36849642-6F718169-4324-44B1-A621-19C3300E6ED2Q36953706-6CA6FF20-07D0-4D54-842B-2F359A139195
P2860
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical validation of the det ...... ns from circulating tumor DNA.
@ast
Clinical validation of the det ...... ns from circulating tumor DNA.
@en
type
label
Clinical validation of the det ...... ns from circulating tumor DNA.
@ast
Clinical validation of the det ...... ns from circulating tumor DNA.
@en
prefLabel
Clinical validation of the det ...... ns from circulating tumor DNA.
@ast
Clinical validation of the det ...... ns from circulating tumor DNA.
@en
P2093
P50
P356
P1433
P1476
Clinical validation of the det ...... ons from circulating tumor DNA
@en
P2093
Alain R Thierry
Anne-Sophie Jarrousse
Brigitte Gillet
Bruno Robert
Caroline Mollevi
Celine Gongora
Denis Pezet
Evelyne Lopez-Crapez
Fanny Rolet
Franck Molina
P2888
P304
P356
10.1038/NM.3511
P407
P577
2014-03-23T00:00:00Z